Orexin Receptor Antagonists

• 

  Subject Areas on Research

  • New Developments in Insomnia Medications of Relevance to Mental Health Disorders. 
  • Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. 
  • Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. 
  • Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.